Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9547530 | 0.89 | SIGMAR1 (0.51) | SIGMAR1CYP1A2CYP3A4KDM4EGAA | |
| SCHEMBL6798279 | 0.87 | SIGMAR1 (0.49) | SIGMAR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28821130 | 0.86 | SIGMAR1 (0.61) | SIGMAR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8502273 | 0.82 | PTPN1 (0.59) | SIGMAR1PTPN1NR4A1NR4A2NR4A3 | |
| SCHEMBL4869612 | 0.81 | SIGMAR1 (0.56) | SIGMAR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11104015 | 0.81 | SIGMAR1 (0.43) | SIGMAR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2237112 | 0.80 | CA2 (0.50) | SIGMAR1 | |
| SCHEMBL34468098 | 0.80 | SIGMAR1 (0.55) | SIGMAR1CYP1A2PTPN1ALDH1A1TDP1 | |
| SCHEMBL7914999 | 0.80 | SIGMAR1 (0.55) | SIGMAR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28017448 | 0.80 | SIGMAR1 (0.55) | SIGMAR1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103214479-A | Pyrazole naphthylurea tyrosine kinase inhibitor and its application | WUHAN DONGYU BIOLOG MEDICAL TECHNOLOGY CO LTD | 2013-07-24 | — | — | CN | disclosed |
| US-20040259875-A1 | Amine derivatives | BAYER HEALTHCARE AG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1414788-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| JP-2003192659-A | PHENYLUREA DERIVATIVE | BAYER AG | 2003-07-09 | — | — | JP | disclosed |
| JP-2003192660-A | UREA DERIVATIVE | BAYER AG | 2003-07-09 | — | — | JP | disclosed |
| JP-2003055209-A | PHENYLNAPHTHYLUREA DERIVATIVE | BAYER AG | 2003-02-26 | — | — | JP | disclosed |
| WO-2003014064-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | AVPR1A, GRIN1, OPRL1 | SIGMAR1 262/4885CYP1A2 3709/4885CYP3A4 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.